U.S. Markets close in 3 hrs

Jim Cramer Says Regeneron is a Better Way to Play it Than Sanofi


Regeneron Pharmaceuticals and its partner Sanofi moved higher in Tuesday trading after announcing an experimental cholesterol-lowering drug had reduced the number of heart attacks and strokes by about half in a clinical trial. Jim Cramer says the injectable drug has multi-billion dollar sales potential when it reaches the market next year. The new drug, alirocumab, is from a new class of medicines. Alirocumab will be used along with other cholesterol drugs that are in the statin class to lower "bad" LDL cholesterol. Sanofi is racing against rival Amgen to get the drug out to market first. Cramer says this is a breakout for Regeneron. He likes Regeneron over Sanofi.